Substantial patent litigation activity occurred in the mRNA space in 2022, involving nearly all of the major mRNA and lipid nanoparticle (LNP) pioneers. Since this is the most significant happening in this space with respect to IP in 2022, this post will provide an overview of that activity as well as a summary exposure analysis.
Recent Posts
- Amici Urge SCOTUS to Scrap Fourth Circuit Approach to Disgorgement of Non-Party Affiliates’ Profits
- Patently Strategic Podcast: Continuation Practice
- GoPro Bid to Invalidate POV Camera Claims as Abstract Shut Down by CAFC
- Wi-Fi 7: Patent Opportunities and the Impact on Intellectual Property in the Technology Sector
- Other Barks & Bites for Friday, September 6: House Version of PERA Introduced; Judicial Council Confirms Extension of Newman Suspension; OpenAI Asks Court to Dismiss Claims and Focus on Fair Use in Copyright Battle